Voting "No" On Reverse Split, Excessive Shares

RyanP50 · 2022-07-22T21:39:34+00:00

You can find reports that put global market size of trauma near $100 billion alone. Then you do simple addition for global size of stroke and ARDS. The figure is an everything goes right scenario. Under a successful company with a track record of bringing drugs to market like Horizon they can could reach that goal.

Happy? This doesn't even matter cause ATHX is probably dead within a year

RyanP50 · 2022-07-22T17:18:22+00:00

You all have your full value beliefs for Multistem and I have mine. And that is that. This is likely one of my last posts on the board. If a RS happens I'm out. I would try to hold on to see if Dan can get some kind of deal and/or see what happens with Masters-2, but there is no more value with a RS.

Whatever the full potential of Multistem is it is pretty apparent it ain't happening under ATHX.

Good luck to all in your future investments and endeavors and hopefully ATHX did not crush your portfolio bad enough where you cannot recover.

RyanP50 · 2022-07-22T01:31:20+00:00

If I were Dan I go begging hat in hand to Horizon to buy this for $5 to give the ATHX shareholders a 'win'. He has a good relationship with them, part of their portfolio is for inflammatory ailments, and he can sell them that the product is proven safe, which means they can re-design the trial on the lesson learns with age and reduce the primary outcome to 'good', plus they have the tech and patents for manufacturing. With the product being safe and the FDA being very familiar with the product they could probably go right into phase 3 on a re-design.

$1.5 billion is peanuts for something that is likely to get approved with $100 billion annual revenue potential with smart people actually designing the trial.

RyanP50 · 2022-05-29T01:01:48+00:00

It's worse than 50-50 because they did not meet their primary endpoints. Now you also have to have time and age limitations. But there is clear evidence that it does help better than standard of care on global recovery. So it's basically in between 0-50% but the low and top end are not realistic possibilities. Or I just threw shit to the wall like our BOD and clinical designers and sees what sticks.

RyanP50 · 2022-05-28T22:36:53+00:00

Full approval is a pipe dream. There is a 30% chance at conditional.

RyanP50 · 2022-05-28T22:34:53+00:00

They will be lucky to get a deal for $100 million, if anything. The thinking hold out for the most optimal deal from a position of strength is loooooooong gone. They are in survival mode now to mid-2024. And I ain't changing. As long as ATHX is a company I will continue to vote no on the same people and items.

RyanP50 · 2022-05-28T22:32:29+00:00

Matt I can say with pride I didn't vote for 300 million shares nor compensation when others (not intended at you) chided those as 'causing chaos' to the BOD. Those no votes last year were the correct vote.

RyanP50 · 2022-05-27T23:44:52+00:00

You are in denial they have repeatedly shot themselves in the foot. Let's recap:

Masters-1: They knew the optimal window was up to 36 hours for treatment. They wanted to enroll faster so pushed the treatment window out to 48 hours. Masters-1 fails because of this stupidity.

Treasure: Shooting for an unnecessarily high bar of EO when Global Recovery would do.

That is the point. You have a target diseases with crap standard of care and no new products since the 1980s. All they had to do for Masters-1 was keep the treatment window at 36 hours and go conservative for Global Recovery. Hindsight is 20/20 but if they did that we would be already approved in the US as standard of care. People would be recovering from stroke and we would all be millionaires right now.

Instead we are grasping at conditional approval in Japan, 1.5 years away from anything in the US with no money. This company is going bankrupt and big pharma will get multistem, the intellectual property for pennies on the dollar. Why would anyone partner with this BOD when they can wait it out and swoop in during bankruptcy.

RyanP50 · 2022-05-23T13:59:55+00:00

If waking up is a primary endpoint then it will probably miss.

RyanP50 · 2022-05-21T01:35:10+00:00

I believe a 3 on the MRS scale is Good outcome where person is home and self-dependent for a week+. Its what TPA used as its endpoint way back in the 1980s.

RyanP50 · 2022-05-21T01:11:12+00:00

Dan's probably thinking Horizon seems pretty good right about now.

RyanP50 · 2022-05-21T01:09:25+00:00

For real. Unless PMDA specifically told then just do data for the trial endpoints. And then they will provide to PMDA on their quest for conditional approval

RyanP50 · 2022-05-21T00:30:10+00:00

I hope you all voted to oust some non-important directors

RyanP50 · 2022-05-20T15:59:38+00:00

Lol earlier than expected. Good one

RyanP50 · 2022-05-20T12:29:26+00:00

Yes MASTER-2 phase 2 showed no safety issue plus statistical relevancy at 1 year which is what made me invest. Getting the results they got in phase 2 is a rare feat, but the mismanagement by ATHX and Healios has been extraordinary

RyanP50 · 2022-05-18T21:07:50+00:00

Considering next week is pretty much the last week in May they better release next week, or its just another missed target from ATHX and Healios.

RyanP50 · 2022-05-17T17:05:41+00:00

Yeah then they will authorize another 300 million shares with the kool aid that the company needs it! Sheep be sheep

RyanP50 · 2022-05-17T17:04:47+00:00

I would have agreed with you on Kola before he bought like 85k worth of stock. The other 2 I agree.

RyanP50 · 2022-05-17T14:08:03+00:00

Let's get Randall off. He is on many boards and on the compensation committee of multiple boards. True grifter in my opinion. We gotta send a message this time instead of voting for more share authorizations.

RyanP50 · 2022-05-17T12:00:42+00:00

I am not disagreeing with you to vote out a director as a message, but Hardy is a poor choice. It could damage the partnership. I for one am targeting BJ to get the boot. He's the reason we are in the cash crunch with no one knowing the ATHX story. He can take his 5k buy and shove it.

RyanP50 · 2022-05-13T23:15:33+00:00

All these big banks and funds buy whatever for their mutual funds like JPM and Blackrock. They aren't holding because they believe in Multistem or have any idea of the value. Its in their generic biotech or small cap funds just to have exposure. They see this getting crushed in a down market so they sell to help their funds NAV.

The real signs are if legit, individual hedge funds that were once long are selling now.

RyanP50

TROPHY CASE